{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreig2l6cv5t5i4627lwga32xsyrgo2eoimyspddh6ru7oiuzfvwco7y",
    "uri": "at://did:plc:k7h5fn3kdhjpj37pc6yhno2o/app.bsky.feed.post/3mphgdqxjreq2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreieznme7rli3l4geunxi4odb64xnb4qfvzt664bqhnuni4f2cs5js4"
    },
    "mimeType": "image/jpeg",
    "size": 146811
  },
  "path": "/article/gene-editing-startups-are-using-crispr-to-treat-diseases/",
  "publishedAt": "2026-06-29T15:00:00.000Z",
  "site": "https://www.scientificamerican.com",
  "textContent": "A handful of start-up firms are testing therapies that target specific epigenetic markers to treat everything from high cholesterol to a rare muscular disorder",
  "title": "Gene-editing startups are using CRISPR to treat diseases"
}